

WE CLAIM:

- 1 1. A unit dosage form for the treatment of herpes simplex and
2 conditions giving rise thereto, said unit dosage form comprising as active ingredients:
 - 3 (a) a thiol-containing glutathione-increasing agent,
 - 4 (b) an L-lysine-increasing agent,
 - 5 (c) a glucosamine-increasing agent, and
 - 6 (d) magnesium.
- 1 2. A unit dosage form in accordance with claim 1 in which said active
2 ingredients are formulated as a substantially homogeneous tablet that releases all of said
3 active ingredients into the stomach upon ingestion for contact with gastric fluid.
- 1 3. A unit dosage form in accordance with claim 1 in which:
 - 2 (a) said thiol-containing glutathione-increasing agent is N-acetyl-
 - 3 L-cysteine,
 - 4 (b) said L-lysine-increasing agent is L-lysine monohydrochloride,
 - 5 (c) said glucosamine-increasing agent is 2-amino-2-deoxy-D-glucose, and
 - 6 (d) said magnesium is in the form of magnesium ascorbate.
- 1 4. A unit dosage form in accordance with claim 1 in which:
 - 2 (a) said thiol-containing glutathione-increasing agent is N-acetyl-
 - 3 L-cysteine in an amount ranging from about 80 mg to about 4000 mg,
 - 4 (b) said L-lysine-increasing agent is L-lysine monohydrochloride in an
5 amount ranging from about 150 mg to about 5000 mg,
 - 6 (c) said glucosamine-increasing agent is 2-amino-2-deoxy-D-glucose in
7 an amount ranging from about 75 mg to about 2500 mg, and
 - 8 (d) said magnesium is in the form of magnesium ascorbate in an amount
9 ranging from about 80 mg to about 3300 mg.
- 1 5. A unit dosage form in accordance with claim 4 in which said active
2 ingredients are formulated as a substantially homogeneous tablet that releases all of said
3 active ingredients into the stomach upon ingestion for contact with gastric fluid.
- 1 6. A unit dosage form in accordance with claim 5 further comprising
2 as an active ingredient quercetin in an amount ranging from about 6 mg to about 300 mg.

1 7. A unit dosage form in accordance with claim 5 further comprising
2 as an active ingredient selenomethionine in an amount ranging from about 0.04 mg to
3 about 1 mg.

1 8. A unit dosage form in accordance with claim 5 further comprising
2 as active ingredients quercetin in an amount ranging from about 6 mg to about 300 mg
3 and selenomethionine in an amount ranging from about 0.05 mg to about 1 mg.

1 9. A unit dosage form in accordance with claim 2 in which
2 (a) said thiol-containing glutathione-increasing agent is
3 L-2-oxothiazolidine-4-carboxylate in an amount ranging from about 80 mg to
4 about 4000 mg,
5 (b) said L-lysine-increasing agent is L-lysine monohydrochloride in an
6 amount ranging from about 150 mg to about 5000 mg,
7 (c) said glucosamine-increasing agent is 2-amino-2-deoxy-D-glucose in
8 an amount ranging from about 75 mg to about 2500 mg, and
9 (d) said magnesium is in the form of magnesium ascorbate in an amount
10 ranging from about 80 mg to about 3300 mg.

1 10. A unit dosage form in accordance with claim 2 in which
2 (a) said thiol-containing glutathione-increasing agent is N-acetyl-
3 L-cysteine in an amount ranging from about 80 mg to about 4000 mg,
4 (b) said L-lysine-increasing agent is L-lysine monohydrochloride in an
5 amount ranging from about 150 mg to about 5000 mg,
6 (c) said glucosamine-increasing agent is 2-amino-2-deoxy-D-glucose in
7 an amount ranging from about 75 mg to about 2500 mg, and
8 (d) said magnesium is in the form of magnesium L-acetylcysteinate in an
9 amount ranging from about 80 mg to about 3300 mg.

1 11. A unit dosage form in accordance with claim 2 in which
2 (a) said thiol-containing glutathione-increasing agent is N-acetyl-
3 L-cysteine in an amount ranging from about 80 mg to about 4000 mg,
4 (b) said L-lysine-increasing agent is L-lysine monohydrochloride in an
5 amount ranging from about 150 mg to about 5000 mg,

6 (c) said glucosamine-increasing agent is 2-amino-2-deoxy-D-glucose in
7 an amount ranging from about 75 mg to about 2500 mg, and

8 (d) said magnesium is in the form of magnesium 2,N-thioctylcysteinate in
9 an amount ranging from about 56 mg to about 2800 mg.

1 12. A unit dosage form in accordance with claim 2 in which

2 (a) said thiol-containing glutathione-increasing agent is N-acetyl-
3 L-cysteine in an amount ranging from about 80 mg to about 4000 mg,

4 (b) said L-lysine-increasing agent is L-lysine monohydrochloride in an
5 amount ranging from about 150 mg to about 5000 mg,

6 (c) said glucosamine-increasing agent is 2-amino-2-deoxy-D-glucose in
7 an amount ranging from about 75 mg to about 2500 mg, and

8 (d) said magnesium is in the form of magnesium 2,N-thioctyltaurate in an
9 amount ranging from about 50 mg to about 2500 mg.

1 13. A unit dosage form in accordance with claim 2 in which

2 (a) said thiol-containing glutathione-increasing agent is N-acetyl-
3 L-cysteine in an amount ranging from about 80 mg to about 4000 mg,

4 (b) said L-lysine-increasing agent is L-lysine monohydrochloride in an
5 amount ranging from about 150 mg to about 5000 mg,

6 (c) said glucosamine-increasing agent is 2-amino-2-deoxy-D-glucose in
7 an amount ranging from about 75 mg to about 2500 mg, and

8 (d) said magnesium is in the form of magnesium taurate in an amount
9 ranging from about 80 mg to about 3400 mg.

1 14. A unit dosage form in accordance with claim 2 in which

2 (a) said thiol-containing glutathione-increasing agent is N-acetyl-
3 L-cysteine in an amount ranging from about 80 mg to about 4000 mg,

4 (b) said L-lysine-increasing agent is L-lysine monohydrochloride in an
5 amount ranging from about 150 mg to about 5000 mg,

6 (c) said glucosamine-increasing agent is 2-amino-2-deoxy-D-glucose in
7 an amount ranging from about 75 mg to about 2500 mg, and

8 (d) said magnesium is in the form of magnesium acetate in an amount
9 ranging from about 175 mg to about 5800 mg.

1 15. A unit dosage form in accordance with claim 2 in which
2 (a) said thiol-containing glutathione-increasing agent is N-acetyl-
3 L-cysteine in an amount ranging from about 80 mg to about 4000 mg,
4 (b) said L-lysine-increasing agent is L-lysine monohydrochloride in an
5 amount ranging from about 150 mg to about 5000 mg,
6 (c) said glucosamine-increasing agent is 2-amino-2-deoxy-D-glucose in
7 an amount ranging from about 75 mg to about 2500 mg, and
8 (d) said magnesium is in the form of magnesium citrate in an amount
9 ranging from about 32 mg to about 1610 mg.

1 16. A unit dosage form in accordance with claim 2 in which
2 (a) said thiol-containing glutathione-increasing agent is N-acetyl-
3 L-cysteine in an amount ranging from about 80 mg to about 4000 mg,
4 (b) said L-lysine-increasing agent is L-lysine monohydrochloride in an
5 amount ranging from about 150 mg to about 5000 mg,
6 (c) said glucosamine-increasing agent is 2-amino-2-deoxy-D-glucose in
7 an amount ranging from about 75 mg to about 2500 mg, and
8 (d) said magnesium is in the form of magnesium oxide in an amount
9 ranging from about 50 mg to about 1600 mg.

1 17. A unit dosage form in accordance with claim 5 further comprising
2 as an active ingredient zinc picolinate present in an amount ranging from about 7.1 mg to
3 about 380 mg.

1 18. A unit dosage form in accordance with claim 5 further comprising
2 as an active ingredient copper sulfate present in an amount ranging from about 0.40 mg to
3 about 14 mg.

1 19. A unit dosage form in accordance with claim 5 further comprising
2 as active ingredients zinc picolinate in an amount ranging from about 7.1 mg to about 380
3 mg and copper sulfate in an amount ranging from about 0.40 mg to about 14 mg.

1 20. A unit dosage form in accordance with claim 17 in which said zinc
2 is in the form of zinc sulfate and is present in an amount ranging from about 3.7 mg to
3 about 198 mg.

1 21. A unit dosage form in accordance with claim 17 in which said zinc
2 is in the form of zinc dinicotinate and is present in an amount ranging from about 7.1 mg
3 to about 380 mg.

1 22. A unit dosage form in accordance with claim 17 in which said zinc
2 is in the form of zinc ascorbate and is present in an amount ranging from about 9.5 mg to
3 about 500 mg.

1 23. A unit dosage form in accordance with claim 17 in which said zinc
2 is in the form of zinc L-acetylcysteinate and is present in an amount ranging from about 9
3 mg to about 480 mg.

1 24. A unit dosage form in accordance with claim 17 in which said zinc
2 is in the form of zinc L-lysinate and is present in an amount ranging from about 8 mg to
3 about 435 mg.

1 25. A unit dosage form in accordance with claim 18 in which said unit
2 dosage form is an oral dosage form and said Cu⁺² is in the form of copper
3 L-acetylcysteinate and is present in an amount ranging from about 1 mg to about 30 mg.

1 26. A unit dosage form in accordance with claim 8 further comprising
2 as an active ingredient zinc picolinate in an amount ranging from about 7.1 mg to about
3 380 mg.

1 27. A unit dosage form in accordance with claim 8 further comprising
2 as an active ingredient copper sulfate in an amount ranging from about 0.40 mg to about
3 14.0 mg.

1 28. A unit dosage form in accordance with claim 8 further comprising
2 as an active ingredient zinc picolinate in an amount ranging from about 7.1 mg to about
3 380 mg and copper sulfate in an amount ranging from about 0.40 mg to about 14.0 mg.

1 29. A layered tablet for the treatment of herpes simplex and conditions
2 giving rise thereto, said layered tablet comprising an immediate-release layer and a
3 sustained-release layer, and comprising the following as active ingredients distributed

4 between said immediate-release layer and said sustained-release layer in the following
5 approximate proportions expressed as relative weight percents:

	<u>Immediate-Release Layer</u>	<u>Sustained-Release Layer</u>
Magnesium L-ascorbate	40-60%	balance
2-Amino-2-deoxy-D-glucose	40-60%	balance
L-lysine monohydrochloride	40-60%	balance
N-acetyl-L-cysteine	40-60%	balance
Quercetin	40-60%	balance
L-Selenomethionine	100%	
Copper sulfate	100%	
Zinc picolinate	40-60%	balance

1 30. A layered tablet for use as an oral dosage form, said layered tablet
2 comprising an immediate-release layer and a sustained-release layer, and comprising the
3 following as active ingredients distributed between said immediate-release layer and said
4 sustained-release layer in the following approximate proportions expressed as relative
5 weight percents:

	<u>Immediate-Release Layer</u>	<u>Sustained-Release Layer</u>
Magnesium taurate	40-60%	balance
L-selenomethionine	100%	
2-Amino-2-deoxy-D-glucose	40-60%	balance
L-Lysine ascorbate	50-60%	balance
Copper sulfate	100%	
Zinc lysinate	40-60%	balance
N-acetyl-L-cysteine	40-60%	balance
Quercetin	40-60%	balance

1 31. A unit dosage form for the treatment of herpes simplex and
2 conditions giving rise thereto, said unit dosage form comprising as active ingredients:


3 (a) a thiol-containing glutathione-increasing agent having the formula

4 RMX

5 in which:

6 R is a member selected from the group consisting of N-acetyl-
7 L-cysteine, L-2-oxothiazolidine-4-carboxylate,
8 N-2(-mercaptopropionyl)-glycine, and L-lysine,
9 M is a member selected from the group consisting of Mg⁺², Cu⁺²,
10 Zn⁺², and Se⁺², and
11 X is a member selected from the group consisting of hydroxide,
12 halide, sulfate, acetate, ascorbate, and bis-ascorbate;
13 (b) an L-lysine-increasing agent,
14 (c) a glucosamine-increasing agent, and
15 (d) magnesium.

1 32. A unit dosage form for the treatment of herpes simplex and
2 conditions giving rise thereto, said unit dosage form comprising as active ingredients:
3 (a) a thiol-containing glutathione-increasing agent having the formula




5 in which:

6 R is a member selected from the group consisting of cysteine,
7 N-acetyl-L-cysteine, L-2-oxothiazolidine-4-carboxylate,
8 N-2(-mercaptopropionyl)-glycine, and L-lysine, and
9 X is a member selected from the group consisting of hydroxide,

10 halide, sulfate, phosphate, acetate, ascorbate, and bis-
11 ascorbate;

12 (b) an L-lysine-increasing agent,
13 (c) a glucosamine-increasing agent, and
14 (d) magnesium.

1 33. A unit dosage form for the treatment of herpes simplex and
2 conditions giving rise thereto, said unit dosage form comprising as active ingredients:
3 (a) a thiol-containing glutathione-increasing agent having the formula



5 in which:

6 R is a member selected from the group consisting of cysteine,
7 acetylcysteine, N-acetyl-cysteine, L-2-oxothiazolidine-


8 4-carboxylate, N-2(-mercaptopropionyl)-glycine, and
9 L-lysine, and

10 X is a member selected from the group consisting of hydroxide,
11 halide, sulfate, phosphate, and acetate;

12 (b) an L-lysine-increasing agent,
13 (c) a glucosamine-increasing agent, and
14 (d) magnesium.

1 34. A unit dosage form for the treatment of herpes simplex and
2 conditions giving rise thereto, said unit dosage form comprising as active ingredients:

3 (a) a thiol-containing glutathione-increasing agent;
4 (b) an L-lysine-increasing agent,
5 (c) a glucosamine-increasing agent,
6 (d) magnesium, and
7 (e) a complex having the formula



8 in which:

9 R is a member selected from the group consisting of cysteine,
10 acetylcysteine, N-acetyl-cysteine, L-2-oxothiazolidine-
11 4-carboxylate, N-2(-mercaptopropionyl)-glycine, and
12 L-lysine, and

13 X is a member selected from the group consisting of hydroxide,
14 halide, sulfate, phosphate, acetate, ascorbate, and bis-
15 ascorbate.

1 35. A unit dosage form for the treatment of herpes simplex and
2 conditions giving rise thereto, said unit dosage form comprising as active ingredients:

3 (a) a thiol-containing glutathione-increasing agent;
4 (b) an L-lysine-increasing agent,
5 (c) a glucosamine-increasing agent,
6 (d) magnesium,
7 (e) copper,
8 (f) zinc, and
9 (g) selenium,

10 at least one of (d), (e), (f), and (g) being in the form of a complex having the formula



11 in which:

13 R is a member selected from the group consisting of

14 2,N-thiocysteine, 2,N-thioctyllysine, and

15 2,N-thiocetyltaurine,

16 n is 1 or 2,

17 M is a member selected from the group consisting of Mg^{+2} , Cu^{+2} ,

18 Zn^{+2} , and Se^{+2} , and

19 X is a member selected from the group consisting of hydroxide,

20 halide, sulfate, acetate, ascorbate, and bis-ascorbate.

1 36. A unit dosage form for the treatment of herpes simplex and
2 conditions giving rise thereto, said unit dosage form being an ophthalmic eyedrop dosage
3 form comprising as active ingredients:

- 4 (a) ascorbic acid,
- 5 (b) 2-amino-2-deoxy-D-glucose,
- 6 (c) zinc sulfate, and
- 7 (d) L-lysine hydrochloride.

1 37. A unit dosage form in accordance with claim 36 in which the
2 concentrations of said active ingredients are as follows:

- 3 (a) about 1.3 $\mu g/mL$ to about 30 $\mu g/mL$ of ascorbic acid,
- 4 (b) about 0.01 mg/mL to about 0.2 mg/mL of 2-amino-2-deoxy-D-
- 5 glucose,
- 6 (c) about 0.06 $\mu g/mL$ to about 8.5 $\mu g/mL$ of zinc sulfate, and
- 7 (d) about 1.6 $\mu g/mL$ to about 23 $\mu g/mL$ of L-lysine hydrochloride.

1 38. A unit dosage form in accordance with claim 37 further comprising
2 as an active ingredient copper sulfate in a concentration ranging from about 0.4 $\mu g/mL$ to
3 about 15 $\mu g/mL$.

1 39. A unit dosage form in accordance with claim 37 further comprising
2 as an active ingredient heparin sodium in a concentration ranging from about 0.6
3 units/mL to about 8 units/mL.

1 40. A unit dosage form in accordance with claim 37 further comprising
2 as active ingredients copper sulfate in a concentration ranging from about 0.4 µg/mL to
3 about 15 µg/mL and heparin sodium in a concentration ranging from about 0.6 units/mL
4 to about 8 units/mL.

1 41. A unit dosage form in accordance with claim 37 further comprising
2 as an active ingredient N-acetyl-L-cysteine in a concentration ranging from about 0.02
3 mg/mL to about 0.5 mg/mL.

1 42. A unit dosage form in accordance with claim 37 further comprising
2 as an active ingredient L-2-oxothiazolidine-4-carboxylate in a concentration ranging from
3 about 0.02 mg/mL to about 0.5 mg/mL.

1 43. A unit dosage form for the treatment of herpes simplex and
2 conditions giving rise thereto, said unit dosage form being an ophthalmic ointment or gel
3 comprising as active ingredients:

- 4 (a) about 1.3 µg/mL to about 30 µg/mL of ascorbic acid,
- 5 (b) about 0.01 mg/mL to about 0.2 mg/mL of 2-amino-2-deoxy-D-
- 6 glucose,
- 7 (c) about 0.06 µg/mL to about 8.5 µg/mL of zinc sulfate, and
- 8 (d) about 1.6 µg/mL to about 23 µg/mL of L-lysine hydrochloride.

1 44. A unit dosage form in accordance with claim 43 further comprising
2 as an active ingredient copper sulfate in a concentration ranging from about 0.4 µg/mL to
3 about 15 µg/mL.

1 45. A unit dosage form in accordance with claim 43 further comprising
2 as an active ingredient quercetin in a concentration ranging from about 0.12 µg/mL to
3 about 2.75 µg/mL.

1 46. A unit dosage form in accordance with claim 43 further comprising
2 as an active ingredient heparin sodium in a concentration ranging from about 0.6
3 units/mL to about 8 units/mL.

1 47. A unit dosage form in accordance with claim 43 further comprising
2 as active ingredients quercetin in a concentration ranging from about 0.12 µg/mL to about

3 2.75 µg/mL and heparin sodium in a concentration ranging from about 0.6 units/mL to
4 about 8 units/mL.

1 48. A unit dosage form in accordance with claim 43 further comprising
2 as active ingredients quercetin in a concentration ranging from about 0.12 µg/mL to about
3 2.75 µg/mL, heparin sodium in a concentration ranging from about 0.6 units/mL to about
4 8 units/mL, and N-acetyl-L-cysteine in a concentration ranging from about 0.02 mg/mL
5 to about 0.5 mg/mL.

1 49. A unit dosage form for the treatment of herpes simplex and
2 conditions giving rise thereto, said unit dosage form being a vaginal dosage form selected
3 from the group consisting of vaginally appropriate suppositories, creams, tablets and gels,
4 comprising as active ingredients:

5 (a) about 1.3 µg/mL to about 30 µg/mL of ascorbic acid,
6 (b) about 0.01 mg/mL to about 0.2 mg/mL of 2-amino-2-deoxy-D-
7 glucose,
8 (c) about 0.06 µg/mL to about 8.5 µg/mL of zinc sulfate, and
9 (d) about 1.6 µg/mL to about 23 µg/mL of L-lysine hydrochloride.

1 50. A unit dosage form in accordance with claim 49 further comprising
2 as an active ingredient copper sulfate in a concentration ranging from about 0.4 µg/mL to
3 about 15 µg/mL.

1 51. A unit dosage form in accordance with claim 49 further comprising
2 as an active ingredient quercetin in a concentration ranging from about 0.12 µg/mL to
3 about 2.75 µg/mL.

1 52. A unit dosage form in accordance with claim 49 further comprising
2 as an active ingredient heparin sodium in a concentration ranging from about 0.6 unit/mL
3 to about 8 units/mL.

1 53. A unit dosage form in accordance with claim 49 further comprising
2 as an active ingredient quercetin in a concentration ranging from about 0.12 µg/mL to
3 about 2.75 µg/mL and heparin sodium in a concentration ranging from about 0.6 unit/mL
4 to about 8 units/mL.

1 54. A unit dosage form in accordance with claim 49 further comprising
2 as an active ingredient quercetin in a concentration ranging from about 0.12 µg/mL to
3 about 2.75 µg/mL, heparin sodium in a concentration ranging from about 0.6 unit/mL to
4 about 8 units/mL, and N-acetylcysteine in a concentration ranging from about 0.6
5 units/mL to about 8 units/mL.

1 55. A unit dosage form for the treatment of herpes simplex and
2 conditions giving rise thereto, said unit dosage form being a mucosal dosage form
3 selected from the group consisting of vaginally appropriate suppositories, creams, tablets
4 and gels, comprising as active ingredients:

5 (a) ascorbic acid,
6 (b) 2-amino-2-deoxy-D-glucose,
7 (c) zinc sulfate, and
8 (d) L-lysine hydrochloride.

1 56. A unit dosage form in accordance with claim 55 in which the
2 concentrations of said active ingredients are as follows:

3 (a) about 1.3 µg/mL to about 30 µg/mL of ascorbic acid,
4 (b) about 0.01 mg/mL to about 0.2 mg/mL of 2-amino-2-deoxy-D-
5 glucose,
6 (c) about 0.06 µg/mL to about 8.5 µg/mL of zinc sulfate, and
7 (d) about 1.6 µg/mL to about 23 µg/mL of L-lysine hydrochloride.

1 57. A unit dosage form in accordance with claim 55 further comprising
2 as an active ingredient copper sulfate in a concentration ranging from about 0.4 µg/mL to
3 about 15 µg/mL.

1 58. A unit dosage form in accordance with claim 55 further comprising
2 as an active ingredient heparin sodium in a concentration ranging from about 0.6
3 units/mL to about 8 units/mL.

1 59. A unit dosage form in accordance with claim 55 further comprising
2 as active ingredients copper sulfate in a concentration ranging from about 0.4 µg/mL to
3 about 15 µg/mL and heparin sodium in a concentration ranging from about 0.6 units/mL
4 to about 8 units/mL.

1 60. A unit dosage form in accordance with claim 55 further comprising
2 as an active ingredient N-acetyl-L-cysteine in a concentration ranging from about 0.02
3 mg/mL to about 0.5 mg/mL.

1 61. A unit dosage form in accordance with claim 55 further comprising
2 as an active ingredient L-2-oxothiazolidine-4-carboxylate in a concentration ranging from
3 about 0.02 mg/mL to about 0.5 mg/mL.

1 62. A unit dosage form for the treatment of herpes simplex and
2 conditions giving rise thereto, said unit dosage form being a topical dermal dosage form
3 selected from the group consisting of topical lotions, gels, creams, and emulsions,
4 comprising as active ingredients:

5 (a) ascorbic acid,
6 (b) 2-amino-2-deoxy-D-glucose,
7 (c) zinc sulfate, and
8 (d) L-lysine hydrochloride.

1 63. A unit dosage form in accordance with claim 62 in which the
2 concentrations of said active ingredients are as follows:

3 (a) about 1.3 µg/mL to about 30 µg/mL of ascorbic acid,
4 (b) about 0.01 mg/mL to about 0.2 mg/mL of 2-amino-2-deoxy-D-
5 glucose,
6 (c) about 0.06 µg/mL to about 8.5 µg/mL of zinc sulfate, and
7 (d) about 1.6 µg/mL to about 23 µg/mL of L-lysine hydrochloride.

1 64. A unit dosage form in accordance with claim 63 further comprising
2 as an active ingredient Cu⁺² in a concentration ranging from about 0.15 µg/mL to about
3 15 µg/mL.

1 65. A unit dosage form in accordance with claim 64 further comprising
2 as an active ingredient quercetin in a concentration ranging from about 0.12 µg/mL to
3 about 2.75 µg/mL.

1 66. A unit dosage form in accordance with claim 65 further comprising
2 as an active ingredient heparin sodium in a concentration ranging from about 0.6 unit/mL
3 to about 8 units/mL.

1 67. A unit dosage form in accordance with claim 66 further comprising
2 as an active ingredient D, α -tocopherol in a concentration ranging from about 16 μ g/mL to
3 about 1600 μ g/mL.

1 68. A unit dosage form in accordance with claim 67 in which said D, α -
2 tocopherol is in the form of D, α -tocopherol nicotinate in a concentration ranging from
3 about 19 μ g/mL to about 2600 μ g/mL.

1 69. A unit dosage form in accordance with claim 67 in which said D, α -
2 tocopherol is in the form of D, α -tocopherol succinate in a concentration ranging from
3 about 19 μ g/mL to about 2500 μ g/mL.